SCHEMBL1821153

SCHEMBL1821153

C[C@@H](OC(=O)[C@@H](N)Cc1ccc(O)cc1)[C@H](N)C(=O)O

nearest known ligand 0.59

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 2/20 0.59
TAAR1 Q96RJ0 3/20 0.47
SLC6A2 P23975 1/20 0.47
ALPI P09923 1/20 0.42
PKM P14618 1/20 0.42
PTGS1 P23219 1/20 0.42
XIAP P98170 1/20 0.42
ESR1 P03372 2/20 0.42
ESR2 Q92731 2/20 0.42
ERAP2 Q6P179 1/20 0.42
LNPEP Q9UIQ6 1/20 0.42
YARS1 P54577 2/20 0.41
TPH1 P17752 1/20 0.41
PCNA P12004 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Tyrosine SCHEMBL16820323 0.91 SLC7A5 (0.63) SLC7A5TAAR1SLC6A2ALPIPKM
Tyrosine SCHEMBL3789571 0.90 SLC7A5 (0.58) SLC7A5TAAR1SLC6A2ALPIPKM
SCHEMBL4586624 0.88 ALPI (0.57) SLC7A5TAAR1SLC6A2ALPIPKM
SCHEMBL4575524 0.88 SLC7A5 (0.56) SLC7A5TAAR1SLC6A2ALPIPKM
SCHEMBL29040629 0.85 SLC7A5 (0.63) SLC7A5TAAR1SLC6A2ALPIPKM
Tyrosine SCHEMBL1267119 0.84 SLC7A5 (0.61) SLC7A5TAAR1SLC6A2ALPIPKM
SCHEMBL17062932 0.83 SLC7A5 (0.59) SLC7A5TAAR1SLC6A2ESR1ESR2
SCHEMBL2058586 0.83 SLC7A5 (0.59) SLC7A5TAAR1SLC6A2ESR1ESR2
SCHEMBL5598391 0.83 SLC7A5 (0.59) SLC7A5TAAR1SLC6A2ESR1ESR2
Lactic Acid SCHEMBL28140583 0.83 SLC7A5 (0.59) SLC7A5TAAR1SLC6A2ALPIPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2023152499-A1 TREATMENT OF TELANGIECTASIA IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) 2023-08-17 WO disclosed
US-20230190714-A1 PRIMARY METHODS AND PROCESSES FOR LIFE EXTENSION IN MODERN-DAY HUMANS POSTREL RICHARD (US) 2023-06-22 US disclosed
WO-2020227588-A1 PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2020-11-12 WO disclosed
US-20200354404-A1 PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2020-11-12 US disclosed
WO-2019182549-A1 PRIMARY METHODS AND PROCESSES FOR LIFE EXTENSION IN MODERN-DAY HUMANS POSTREL RICHARD (US) 2019-09-26 WO disclosed
US-10253320-B2 Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1 CURNA, INC. (US) 2019-04-09 US disclosed
CN-103732534-B Cellular structure body and manufacture method thereof 味之素株式会社 2016-09-28 CN disclosed
US-8843356-B2 Computer systems and methods for associating genes with traits using cross species data MERCK SHARP & DOHME CORP. (US) 2014-09-23 US disclosed
US-8541649-B2 Brassinosteroid regulated kinases (BRKs) that mediate brassinosteroid signal transduction and uses thereof CARNEGIE INSTITUTION OF WASHINGTON (US) 2013-09-24 US disclosed
EP-2564865-A1 Methods of Modulating Cellular Homeostatic Pathways and Cellular Survival Dana-Farber Cancer Institute, Inc. (US) 2013-03-06 EP disclosed
EP-2315770-A2 BRASSINOSTEROID REGULATED KINASES (BRKS) THAT MEDIATE BRASSINOSTEROID SIGNAL TRANSDUCTION AND USES THEREOF Carnegie Institution Of Washington (US) 2011-05-04 EP disclosed
US-20100043097-A1 Brassinosteroid Regulated Kinases (BRKs) That Mediate Brassinosteroid Signal Transduction and Uses Thereof CARNEGIE INSTITUTION OF WASHINGTON (US) 2010-02-18 US disclosed
WO-2010011285-A2 BRASSINOSTEROID REGULATED KINASES (BRKS) THAT MEDIATE BRASSINOSTEROID SIGNAL TRANSDUCTION AND USES THEREOF CARNEGIE INSTITUTION OF WASHINGTON (US) 2010-01-28 WO disclosed
EP-1641930-A4 NUCLEIC ACID SEQUENCES ENCODING PROTEINS ASSOCIATED WITH ABIOTIC STRESS RESPONSE AND PLANT CELLS AND PLANTS WITH INCREASED TOLERANCE TO ENVIRONMENTAL STRESS BASF PLANT SCIENCE GMBH (DE) 2008-06-11 EP disclosed
CN-101039702-A Heat shock protein as a targeting agent for endothelium-specific in vivo transduction GEN ELECTRIC (US) 2007-09-19 CN disclosed
EP-1641930-A2 NUCLEIC ACID SEQUENCES ENCODING PROTEINS ASSOCIATED WITH ABIOTIC STRESS RESPONSE AND PLANT CELLS AND PLANTS WITH INCREASED TOLERANCE TO ENVIRONMENTAL STRESS BASF Plant Science GmbH (DE) 2006-04-05 EP disclosed
EP-1601974-A2 DIFFERENTIAL MEGAPLEX IMMUNOASSAY TCP Innovations Limited (GB) 2005-12-07 EP disclosed
WO-2004092398-A2 NUCLEIC ACID SEQUENCES ENCODING PROTEINS ASSOCIATED WITH ABIOTIC STRESS RESPONSE AND PLANT CELLS AND PLANTS WITH INCREASED TOLERANCE TO ENVIRONMENTAL STRESS BASF PLANT SCIENCE GMBH (DE) 2004-10-28 WO disclosed
WO-2004081025-A2 DIFFERENTIAL MEGAPLEX IMMUNOASSAY TCP INNOVATIONS LIMITED (GB) 2004-09-23 WO disclosed
US-5171837-A Treatment of autoimmune diseases KURARAY CO., LTD. (JP) 1992-12-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100043097-A1 Brassinosteroid Regulated Kinases (BRKs) That Mediate Brassinosteroid Signal Transduction and Uses Thereof BRSK2, BRSK1, BLK SLC7A5 4361/4885TAAR1 2688/4885SLC6A2 4819/4885
US-20200354404-A1 PEPTIDOMIMETIC AGENTS, SYNTHESIS AND USES THEREOF DNPEP, PEPD, ANPEP SLC7A5 1891/4885TAAR1 3517/4885SLC6A2 4336/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.